Triflumizole is an imidazole pesticide/fungicide with broad antifungal activity. Triflumizole exhibits additional activities in vitro. Triflumizole inhibits the ubiquitin-proteasome system, inducing variation into skp1 protein expression and increasing the risk for Parkinson’s disease. Triflumizole also activates PPARγ, inducing adipogenesis in vitro and in vivo. This compound also displays immunomodulatory activity, acting as an inverse agonist at retinoid acid receptor-related orphan receptor RORγ and inhibiting expression of IL-17 in vitro. Like many azole fungicides, triflumizole likely inhibits 14-α demethylase, inhibiting ergosterol production and fungal cell wall synthesis. Additionally, triflumizole may inhibit aromatase.